AbCellera Biologics Inc (ABCL) concluded trading on Wednesday at a closing price of $3.23, with 20.07 million shares of worth about $64.82 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 7.67% during that period and on June 11, 2025 the price saw a gain of about 6.95%. Currently the company’s common shares owned by public are about 298.36M shares, out of which, 223.95M shares are available for trading.
Stock saw a price change of 33.47% in past 5 days and over the past one month there was a price change of 56.80%. Year-to-date (YTD), ABCL shares are showing a performance of 10.24% which decreased to -10.77% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.89 but also hit the highest price of $3.68 during that period. The average intraday trading volume for AbCellera Biologics Inc shares is 4.24 million. The stock is currently trading 44.55% above its 20-day simple moving average (SMA20), while that difference is up 42.63% for SMA50 and it goes to 21.72% higher than SMA200.
AbCellera Biologics Inc (NASDAQ: ABCL) currently have 298.36M outstanding shares and institutions hold larger chunk of about 41.09% of that.
The stock has a current market capitalization of $964.11M and its 3Y-monthly beta is at 0.42. It has posted earnings per share of -$0.57 in the same period. It has Quick Ratio of 10.15 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABCL, volatility over the week remained 7.40% while standing at 5.06% over the month.
Stock’s fiscal year EPS is expected to drop by -10.77% while it is estimated to increase by 10.02% in next year. EPS is likely to grow at an annualized rate of 0.83% for next 5-years, compared to annual growth of -107.74% made by the stock over the past 5-years.
Coverage by The Benchmark Company stated AbCellera Biologics Inc (ABCL) stock as a Buy in their note to investors on February 22, 2024, suggesting a price target of $9 for the stock. Stock get an Overweight rating from Piper Sandler on October 13, 2023.
